COSMOS Pharmaceutical Corporation (3349.T)

9053.0035.00 (-0.39%)

COSMOS Pharmaceutical Corporation (3349.T) stock comprehensive Profitability Analysis including gross margin, operating margin, net margin, return on assets, return on equity, return on invested capital. Compare profitability against peers/competitors, industry and sector standards.

Low Bankruptcy RiskLow ProfitabilityEfficient OperationsModerate GrowthModerate QualityAdequate Dividend ProfileIndustry Rank: 67.57%Sector Rank: 75.68%

JPX - Healthcare - Medical - Pharmaceuticals | Market Cap: 717.52B | Next Earnings Date: 14 Oct 2025

Day's Range

8935.00 - 9125.00

52-Week Range

6347.00 - 10045.00

Volume

380.0K / 335.9K (Avg.)

P/E Ratio | EPS

23.15 | 391.09

Trending:

3349.T Profitability Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.

Return on Equity (ROE)

3.43%

Increased from previous period

ROE above 1.5x 3088.T's 2.26%. David Dodd would confirm if such superior profitability is sustainable.

Return on Assets (ROA)

1.68%

Increased from previous period

Similar ROA to 3088.T's 1.63%. Peter Lynch might expect similar cost structures or operational dynamics.

Return on Capital Employed (ROCE)

4.32%

Increased from previous period

ROCE 1.25-1.5x 3088.T's 3.18%. Bruce Berkowitz would confirm if the firm’s capital structure drives superior returns.

Gross Profit Margin

20.84%

Increased from previous period

Gross margin 50-75% of 3088.T's 34.36%. Martin Whitman would worry about a persistent competitive disadvantage.

Operating Profit Margin

4.42%

Increased from previous period

Operating margin 50-75% of 3088.T's 6.71%. Martin Whitman would question competitiveness or cost discipline.

Net Profit Margin

3.11%

Increased from previous period

Net margin 50-75% of 3088.T's 4.49%. Martin Whitman would question if fundamental disadvantages limit net earnings.

Select Chart Metric:

3349.T Profitability Analysis - Compare Against 3088.T

Comparison against 3088.T

None 3391.T 3141.T 3088.T 2127.T 9843.T

Return on Equity (ROE)

3.43%

Increased from previous period

ROE above 1.5x 3088.T's 2.26%. David Dodd would confirm if such superior profitability is sustainable.

Return on Assets (ROA)

1.68%

Increased from previous period

Similar ROA to 3088.T's 1.63%. Peter Lynch might expect similar cost structures or operational dynamics.

Return on Capital Employed (ROCE)

4.32%

Increased from previous period

ROCE 1.25-1.5x 3088.T's 3.18%. Bruce Berkowitz would confirm if the firm’s capital structure drives superior returns.

Gross Profit Margin

20.84%

Increased from previous period

Gross margin 50-75% of 3088.T's 34.36%. Martin Whitman would worry about a persistent competitive disadvantage.

Operating Profit Margin

4.42%

Increased from previous period

Operating margin 50-75% of 3088.T's 6.71%. Martin Whitman would question competitiveness or cost discipline.

Net Profit Margin

3.11%

Increased from previous period

Net margin 50-75% of 3088.T's 4.49%. Martin Whitman would question if fundamental disadvantages limit net earnings.

Select Chart Metric: